Aminophylline Shows Short-Term Benefits in Asphyxiated Newborns, but Fails to Prevent Acute Kidney Injury: Study

For this purpose, the researchers conducted an open-label randomized clinical trial involving term neonates with severe asphyxia (n = 41). These infants received an intravenous dose of aminophylline at 5 mg/kg within the first hour after birth, alongside standard care for birth asphyxia. The control group (n = 40) received standard care alone.

The study monitored and compared various parameters, including daily urine output, weight, serum creatinine levels, renal function status, and complications during the first five days of life. Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 25.

Key observations from the study are as follows:

• Approximately 24.39% of neonates in the aminophylline group developed acute kidney injury, compared to 35.0% in the control group.
• While urine output was generally higher in the aminophylline-treated newborns than in those receiving standard care, this difference did not reach statistical significance.
• The most pronounced variations in urine output were noted on the second and third postnatal days.
• The changes in plasma creatinine levels between the two groups during this period were also not statistically significant.

"Based on our study findings, we recommend that aminophylline therapy in this context should be restricted to research settings and not employed as a preventive measure," the researchers concluded.

Reference:

Munian, D., Dutta, S., Ghosh, A., & Saha, R. (2024). Role of aminophylline in prevention of acute kidney injury in term neonates with severe perinatal asphyxia: A randomized open-label controlled trial. Journal of Tropical Pediatrics, 70(6). https://doi.org/10.1093/tropej/fmae036